GVHD
Clinical trials for GVHD explained in plain language.
Never miss a new study
Get alerted when new GVHD trials appear
Sign up with your email to follow new studies for GVHD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising new combo aims to prevent deadly transplant complication
Disease control CompletedThis study tested a new drug combination (pacritinib, sirolimus, and tacrolimus) to prevent graft-versus-host disease (GVHD) in 40 blood cancer patients receiving a stem cell transplant from a matched donor. GVHD is a serious condition where donor cells attack the patient's body.…
Matched conditions: GVHD
Phase: PHASE1, PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 17, 2026 05:34 UTC
-
New drug cocktail aims to stop transplant rejection in blood cancer patients
Disease control CompletedThis study tested whether a combination of two drugs, cyclophosphamide and abatacept, could lower the chance of developing chronic graft-versus-host disease (GVHD) after a stem cell transplant. GVHD happens when donor cells attack the patient's body. The trial included 43 adults …
Matched conditions: GVHD
Phase: PHASE2 • Sponsor: Dimitrios Tzachanis, MD PhD • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New drug combo shows promise in preventing transplant complications
Disease control CompletedThis early-phase study tested whether adding a drug called BMS-986004 (which blocks CD40-L) to standard immune-suppressing medicine could help prevent acute graft-versus-host disease (GVHD) in 45 adults with blood cancers or disorders receiving a stem cell transplant. GVHD is a s…
Matched conditions: GVHD
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
Blood test may forecast Graft-Versus-Host disease risk
Knowledge-focused CompletedThis study looked at 50 adults receiving a stem cell transplant for blood cancer. Researchers checked if the number of certain cells in the blood before transplant could predict the risk of a serious complication called graft-versus-host disease (GVHD). The goal was to see if thi…
Matched conditions: GVHD
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated May 14, 2026 12:05 UTC
-
Scientists engineer 'smarter' IL-2 to tame overactive immune systems
Knowledge-focused CompletedThis study tested specially engineered versions of a natural immune protein (IL-2) in blood samples from 67 people with autoimmune or inflammatory diseases like lupus, multiple sclerosis, and rheumatoid arthritis. The goal was to see if these modified proteins could selectively a…
Matched conditions: GVHD
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Apr 24, 2026 16:18 UTC